Trust Point Inc. Reduces Position in Repligen Co. (NASDAQ:RGEN)

Trust Point Inc. decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 26.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,786 shares of the biotechnology company’s stock after selling 2,107 shares during the period. Trust Point Inc.’s holdings in Repligen were worth $833,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of RGEN. UMB Bank n.a. increased its stake in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. increased its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the period. Resources Management Corp CT ADV purchased a new position in Repligen in the 3rd quarter worth about $37,000. Quarry LP boosted its position in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares during the period. Finally, nVerses Capital LLC bought a new position in Repligen in the 3rd quarter worth about $45,000. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on RGEN. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, HC Wainwright cut their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $184.73.

Repligen Stock Up 0.1 %

Repligen stock opened at $160.02 on Wednesday. The business has a fifty day moving average price of $154.78 and a 200-day moving average price of $148.32. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The stock has a market capitalization of $8.97 billion, a price-to-earnings ratio of -432.47, a PEG ratio of 4.67 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.23 earnings per share. Equities research analysts forecast that Repligen Co. will post 1.54 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.